Latest news with #IntelliaTherapeutics'
Yahoo
11-05-2025
- Business
- Yahoo
Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report
Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, Intellia Therapeutics also reported a statutory loss of US$1.10 per share, which at least was smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. Our free stock report includes 2 warning signs investors should be aware of before investing in Intellia Therapeutics. Read for free now. After the latest results, the 24 analysts covering Intellia Therapeutics are now predicting revenues of US$50.0m in 2025. If met, this would reflect a meaningful 9.8% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 14% from last year to US$4.35. Before this earnings announcement, the analysts had been modelling revenues of US$49.3m and losses of US$4.71 per share in 2025. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged. See our latest analysis for Intellia Therapeutics There's been no major changes to the consensus price target of US$40.56, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Intellia Therapeutics, with the most bullish analyst valuing it at US$106 and the most bearish at US$8.00 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Intellia Therapeutics' growth to accelerate, with the forecast 13% annualised growth to the end of 2025 ranking favourably alongside historical growth of 0.03% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 18% per year. So it's clear that despite the acceleration in growth, Intellia Therapeutics is expected to grow meaningfully slower than the industry average. The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Intellia Therapeutics' revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Intellia Therapeutics going out to 2027, and you can see them free on our platform here. You should always think about risks though. Case in point, we've spotted 2 warning signs for Intellia Therapeutics you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
28-03-2025
- Health
- Associated Press
CRISPR Cas9 Market Research Report 2024: Positioned for Exponential Growth with Advancements in Gene Therapy - Outlook to 2029
The 'CRISPR Cas9 Market' report has been added to offering. In a recent industry analysis, the medical community has witnessed significant progress in the area of CRISPR/Cas9 therapies. Experts predict that with several therapies demonstrating efficacy and safety, the market is positioned to welcome a new wave of regulatory approvals in the next half-decade. Market Expansion and Clinical Trials Stemming from demanding medical needs and the growing number of genetic disorders worldwide, CRISPR/Cas9 therapies are experiencing a rapid ascension in clinical trials and applications. This not only includes the management of cancers and genetic diseases but is expanding to address cardiovascular, neurodegenerative, and CNS diseases as well. Innovations and Therapeutic Applications CRISPR/Cas9's revolutionary gene-editing capabilities are forecasted to transform numerous medical and biotechnological fields, as ongoing clinical trials progress towards late-stage development. For example, Intellia Therapeutics' latest phase III study on NTLA-2001 promises to be a landmark in gene therapy for transthyretin amyloidosis with cardiomyopathy. Market Projections and Financial Implications The market for CRISPR/Cas9 therapies is estimated to grow significantly, potentially becoming a multi-billion-dollar industry. The US currently leads in research and development activities, but other regions like the EU are rapidly progressing. The first commercial CRISPR/Cas9 therapy, Casgevy, has been introduced at a considerable cost, reflective of its innovative value and therapeutic potential. Conclusion and Future Prospects CRISPR/Cas9 therapies represent a bold step forward for medical science, with the backing of crucial industry players and increasing technological advancements. This burgeoning field promises new treatments for patients across a spectrum of conditions, aligning with investments, collaborations, and strategic market movements within the pharmaceutical and biotechnology sectors. The next decade is set to be transformative for CRISPR/Cas9 therapy and its applications in the fight against disease. Keep abreast of the market's growth and upcoming clinical trials advances for a brighter future in health treatments and therapies. This significant leap in genetic editing isn't just a milestone for the industry—it's a harbinger of hope for patients worldwide. A selection of companies mentioned in this report includes, but is not limited to: 4D Molecular Therapeutics Arbor Biotechnologies ASC Therapeutics C4U Corporation Casebia Therapeutics CRISPR Therapeutics Editas Medicine Intellia Therapeutics Nkarta Therapeutics Vertex Pharmaceuticals For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 03/28/2025 09:09 AM/DISC: 03/28/2025 09:09 AM
